Back

Circulating low-grade inflammation in human pulmonary arterial hypertension promotes eNOS-NO/ROS imbalance: Involvement of the angiotensin and the endothelin pathways and prevention by EPA:DHA 6:1

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Pathophysiology and treatment Drugs, Drug Targets HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Hira MUZAMMEL

Strasbourg (France)

6 More presentations in this session

Presentation thumbnail
Inflamed atrial tissues of patients with atrial fibrillation are characterized by pro-oxidant and pro-remodeling responses: synergistic inhibition by an SGLT2 inhibitor plus a GLP-1R activation
Doctor W. Fakih (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodeling
Professor E. Jones (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
L-PGDS/ PGD2 is a regulator of cardiac metabolism during aging?
Doctor L. Savchenko (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Reversal of age-related diastolic dysfunction by micronized purified flavonoid fraction in rats with attenuation of low-grade inflammation, eNOS-NO/ROS imbalance, and left ventricular fibrosis
Professor V. Schini-Kerth (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Effect of SGLT2i on myocardial remodeling due to cardiorenal syndrome in rat model of heart failure
Doctor M. Sykora (Bratislava, SK)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology and treatment

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
EPA:DHA 6:1 prevents right ventricular dysfunction and lung vascular remodeling in monocrotaline-induced pulmonary arterial hypertension in rats by mitigating inflammatory and pro-oxidant responses
thumbnail
Congress Presentation
Pathobiological characterization of pulmonary hypertension associated with heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Effects of BET Inhibition on lung micro-environmental changes in obesity-related pulmonary Arterial Hypertension (PAH)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources